Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kelch-like protein 4 (KLHL4) is a cytoskeletal-associated protein encoded on the X chromosome, containing six Kelch repeats and a BTB/POZ domain, typical of its family[1][4][7]. These domains facilitate protein-protein interactions, including dimerization and adapter functions for ubiquitin ligases[3][4]. KLHL4 is expressed in several fetal tissues, including tongue and palate, and has been associated with congenital X-linked cleft palate (CPX)[4]. It mediates interactions with Cul3 E3 ligase and is shown to regulate cell-cycle progression by activating transcription of p21 through enhancement of p53 pathway activity[2][4]. Although the precise biological function is still under investigation, KLHL4 and its family members play roles in cytoskeletal organization, gene expression, and protein ubiquitination[3][7]. No drugs, biomarkers, or therapeutic safety data are currently associated with KLHL4, reflecting its status as a non-canonical drug target as of 2024[2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kelch-like protein 4 (KLHL4).